Cargando…
Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
Clinical trials and studies have shown that postmenopausal women undergoing combination hormone replacement therapy containing estrogen and progestin have an increased risk of breast cancer compared with women taking estrogen or placebo alone. Using animal models, we have previously shown that synth...
Autores principales: | Liang, Yayun, Goyette, Sandy, Hyder, Salman M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511027/ https://www.ncbi.nlm.nih.gov/pubmed/28744156 http://dx.doi.org/10.2147/BCTT.S140265 |
Ejemplares similares
-
Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells
por: Liang, Yayun, et al.
Publicado: (2016) -
Cholesterol biosynthesis inhibitor RO 48-8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway
por: Ding, Zhen, et al.
Publicado: (2021) -
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts
por: Cook, Matthew T., et al.
Publicado: (2015) -
Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro
por: Goyette, Sandy, et al.
Publicado: (2017) -
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development
por: CARROLL, CANDACE E., et al.
Publicado: (2012)